Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...
A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...
4D Molecular Therapeutics reports positive interim data for 4D-150 in wet AMD and DME, with strong financial position and strategic focus. 4D Molecular Therapeutics announced positive interim data for ...
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of ...
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ...
Please provide your email address to receive an email when new articles are posted on . EyePoint Pharmaceuticals has announced positive 16-week data from the ongoing phase 2 VERONA trial evaluating ...
Image source: The Motley Fool. EyePoint Pharmaceuticals (NASDAQ:EYPT) advanced its lead candidate, DuraVu, through rapid phase 3 enrollment in wet AMD and aligned phase 3 DME trial initiation while ...
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced final 20-week study completion data from its randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results